Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
DrugPatentWatch has published a paper on global biopharmaceutical productivity in the latest issue of Nature Biotechnology.
This paper is a refinement of prior work ranking international biotechnology for Scientific American Worldview, and draws on the DrugPatentWatch database.
In this paper DrugPatentWatch investigates the locations of drug inventors, as measured by patents covering marketed drugs. The result, which may surprise many readers, is that the bulk of the innovation still occurs in the legacy pharma regions — Western Europe, the United States, and Japan.
Given the poor output of patents covering marketed drugs from countries such as China, one must ask whether vigorous pro-patenting policies (China leads the world in patent applications — but not in grants) are appropriate. Additionally, one must ask if Western metrics for innovation should be applied to other contexts.
To access the full paper (paywall), see http://www.nature.com/nbt/journal/v32/n6/full/nbt.2933.html